Mathai Mammen, M.D., Ph.D.

Mathai Mammen, M.D., Ph.D., serves as the CEO, President, and Chairman of Parabilis Medicines since June 2023, focusing on discovering and developing impactful medicines for patients. Mammen is also a member of the Board of Directors for Kelonia Therapeutics, Xaira Therapeutics, and Sandoz, while holding an Executive Advisor position at General Atlantic and previously contributing to 10x Genomics and Johnson & Johnson. Notably, Mammen was Executive Vice President of Pharmaceuticals and R&D at Johnson & Johnson from June 2017 to February 2023, overseeing significant advancements in the company's pharmaceutical R&D. Mammen's extensive experience includes senior leadership roles at Merck, Theravance Biopharma, and Innoviva, alongside academic credentials from prestigious institutions including Harvard Medical School, Harvard University, MIT, and Dalhousie University.